Copyright Reports & Markets. All rights reserved.

Global Personalized Medicines Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Personalized Medicines Industry
  • 1.7 COVID-19 Impact: Personalized Medicines Market Trends

    • 2 Global Personalized Medicines Quarterly Market Size Analysis

    • 2.1 Personalized Medicines Business Impact Assessment - COVID-19
      • 2.1.1 Global Personalized Medicines Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Personalized Medicines Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Personalized Medicines Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Personalized Medicines Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Personalized Medicines Market
    • 3.4 Key Players Personalized Medicines Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Personalized Medicines Segments, By Type

    • 4.1 Introduction
      • 1.4.1 PM Diagnostics
      • 1.4.2 PM Therapeutics
      • 1.4.3 Personalized Medical Care
      • 1.4.4 Personalized Nutrition & Wellness
    • 4.2 By Type, Global Personalized Medicines Market Size, 2019-2021

    5 Impact of Covid-19 on Personalized Medicines Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals Pharmacies
      • 5.5.2 Retail Pharmacies
      • 5.5.3 Dietary Care Centers
      • 5.5.4 Others
    • 5.2 By Application, Global Personalized Medicines Market Size, 2019-2021
      • 5.2.1 By Application, Global Personalized Medicines Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 3G Biotech
      • 7.1.1 3G Biotech Business Overview
      • 7.1.2 3G Biotech Personalized Medicines Quarterly Revenue, 2020
      • 7.1.3 3G Biotech Personalized Medicines Product Introduction
      • 7.1.4 3G Biotech Response to COVID-19 and Related Developments
    • 7.2 Quest Diagnostics
      • 7.2.1 Quest Diagnostics Business Overview
      • 7.2.2 Quest Diagnostics Personalized Medicines Quarterly Revenue, 2020
      • 7.2.3 Quest Diagnostics Personalized Medicines Product Introduction
      • 7.2.4 Quest Diagnostics Response to COVID-19 and Related Developments
    • 7.3 Laboratory Corporation of America
      • 7.3.1 Laboratory Corporation of America Business Overview
      • 7.3.2 Laboratory Corporation of America Personalized Medicines Quarterly Revenue, 2020
      • 7.3.3 Laboratory Corporation of America Personalized Medicines Product Introduction
      • 7.3.4 Laboratory Corporation of America Response to COVID-19 and Related Developments
    • 7.4 Abbott
      • 7.4.1 Abbott Business Overview
      • 7.4.2 Abbott Personalized Medicines Quarterly Revenue, 2020
      • 7.4.3 Abbott Personalized Medicines Product Introduction
      • 7.4.4 Abbott Response to COVID-19 and Related Developments
    • 7.5 Agendia NV
      • 7.5.1 Agendia NV Business Overview
      • 7.5.2 Agendia NV Personalized Medicines Quarterly Revenue, 2020
      • 7.5.3 Agendia NV Personalized Medicines Product Introduction
      • 7.5.4 Agendia NV Response to COVID-19 and Related Developments
    • 7.6 Asuragen Inc
      • 7.6.1 Asuragen Inc Business Overview
      • 7.6.2 Asuragen Inc Personalized Medicines Quarterly Revenue, 2020
      • 7.6.3 Asuragen Inc Personalized Medicines Product Introduction
      • 7.6.4 Asuragen Inc Response to COVID-19 and Related Developments
    • 7.7 Becton Dickinson
      • 7.7.1 Becton Dickinson Business Overview
      • 7.7.2 Becton Dickinson Personalized Medicines Quarterly Revenue, 2020
      • 7.7.3 Becton Dickinson Personalized Medicines Product Introduction
      • 7.7.4 Becton Dickinson Response to COVID-19 and Related Developments
    • 7.8 CardioDx Inc.
      • 7.8.1 CardioDx Inc. Business Overview
      • 7.8.2 CardioDx Inc. Personalized Medicines Quarterly Revenue, 2020
      • 7.8.3 CardioDx Inc. Personalized Medicines Product Introduction
      • 7.8.4 CardioDx Inc. Response to COVID-19 and Related Developments
    • 7.9 Foundation Medicine
      • 7.9.1 Foundation Medicine Business Overview
      • 7.9.2 Foundation Medicine Personalized Medicines Quarterly Revenue, 2020
      • 7.9.3 Foundation Medicine Personalized Medicines Product Introduction
      • 7.9.4 Foundation Medicine Response to COVID-19 and Related Developments
    • 7.10 Qiagen
      • 7.10.1 Qiagen Business Overview
      • 7.10.2 Qiagen Personalized Medicines Quarterly Revenue, 2020
      • 7.10.3 Qiagen Personalized Medicines Product Introduction
      • 7.10.4 Qiagen Response to COVID-19 and Related Developments
    • 7.11 Siemens Healthcare
      • 7.11.1 Siemens Healthcare Business Overview
      • 7.11.2 Siemens Healthcare Personalized Medicines Quarterly Revenue, 2020
      • 7.11.3 Siemens Healthcare Personalized Medicines Product Introduction
      • 7.11.4 Siemens Healthcare Response to COVID-19 and Related Developments
    • 7.12 Amgen
      • 7.12.1 Amgen Business Overview
      • 7.12.2 Amgen Personalized Medicines Quarterly Revenue, 2020
      • 7.12.3 Amgen Personalized Medicines Product Introduction
      • 7.12.4 Amgen Response to COVID-19 and Related Developments
    • 7.13 Bristol-Myers Squibb
      • 7.13.1 Bristol-Myers Squibb Business Overview
      • 7.13.2 Bristol-Myers Squibb Personalized Medicines Quarterly Revenue, 2020
      • 7.13.3 Bristol-Myers Squibb Personalized Medicines Product Introduction
      • 7.13.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.14 GE Healthcare
      • 7.14.1 GE Healthcare Business Overview
      • 7.14.2 GE Healthcare Personalized Medicines Quarterly Revenue, 2020
      • 7.14.3 GE Healthcare Personalized Medicines Product Introduction
      • 7.14.4 GE Healthcare Response to COVID-19 and Related Developments
    • 7.15 Pfizer
      • 7.15.1 Pfizer Business Overview
      • 7.15.2 Pfizer Personalized Medicines Quarterly Revenue, 2020
      • 7.15.3 Pfizer Personalized Medicines Product Introduction
      • 7.15.4 Pfizer Response to COVID-19 and Related Developments
    • 7.16 Sanofi
      • 7.16.1 Sanofi Business Overview
      • 7.16.2 Sanofi Personalized Medicines Quarterly Revenue, 2020
      • 7.16.3 Sanofi Personalized Medicines Product Introduction
      • 7.16.4 Sanofi Response to COVID-19 and Related Developments
    • 7.17 23andMe
      • 7.17.1 23andMe Business Overview
      • 7.17.2 23andMe Personalized Medicines Quarterly Revenue, 2020
      • 7.17.3 23andMe Personalized Medicines Product Introduction
      • 7.17.4 23andMe Response to COVID-19 and Related Developments
    • 7.18 Illumina
      • 7.18.1 Illumina Business Overview
      • 7.18.2 Illumina Personalized Medicines Quarterly Revenue, 2020
      • 7.18.3 Illumina Personalized Medicines Product Introduction
      • 7.18.4 Illumina Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Personalized Medicines, including the following market information:
      Global Personalized Medicines Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Personalized Medicines Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Personalized Medicines Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Personalized Medicines Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include 3G Biotech, Quest Diagnostics, Laboratory Corporation of America, Abbott, Agendia NV, Asuragen Inc, Becton Dickinson, CardioDx Inc., Foundation Medicine, Qiagen, Siemens Healthcare, Amgen, Bristol-Myers Squibb, GE Healthcare, Pfizer, Sanofi, 23andMe, Illumina, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      PM Diagnostics
      PM Therapeutics
      Personalized Medical Care
      Personalized Nutrition & Wellness

      Based on the Application:
      Hospitals Pharmacies
      Retail Pharmacies
      Dietary Care Centers
      Others

      Buy now